Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID Reference, 4th edition, 372 pages

+ the daily Top 10

  Lung Cancer

  Free Subscription


2 AJR Am J Roentgenol
1 Ann Surg
8 Ann Thorac Surg
2 Anticancer Res
1 Cancer
2 Cancer Cell
1 Cancer Lett
1 Chest
1 Clin Cancer Res
2 Clin Lung Cancer
3 Eur J Cancer
1 Int J Cancer
6 J Cancer Res Clin Oncol
1 J Nucl Med
2 J Thorac Cardiovasc Surg
5 Lung Cancer
5 PLoS One
1 Thorax

  Retrieve available abstracts of this week’s articles:
HTML format
Single Articles

    AJR Am J Roentgenol

  1. MENDOZA DP, Heeger A, Mino-Kenudson M, Lanuti M, et al
    Clinicopathologic and Longitudinal Imaging Features of Lung Cancer Associated with Cystic Airspaces: A Systematic Review and Meta-Analysis.
    AJR Am J Roentgenol. 2020 Jul 29. doi: 10.2214/AJR.20.23835.
    PubMed         Abstract available

  2. MORTANI BARBOSA EJ JR, Yang R, Hershman M
    Real World Lung Cancer CT Screening Performance, Smoking Behavior, and Adherence to Recommendations: Lung-RADS Category and Smoking Status Predict Adherence.
    AJR Am J Roentgenol. 2020 Jul 15. doi: 10.2214/AJR.20.23637.
    PubMed         Abstract available

    Ann Surg

  3. RAKOVICH G, Urbanowicz R, Issa R, Wang HT, et al
    Minimizing the Risk of Aerosol Contamination During Elective Lung Resection Surgery.
    Ann Surg. 2020;272:e125-e128.
    PubMed         Abstract available

    Ann Thorac Surg

  4. DUBOIS RL, Raisig E, Stanifer BP
    Gossypiboma Mimicking Fluorodeoxyglucose-avid Lung Nodule.
    Ann Thorac Surg. 2020;109:e403-e405.
    PubMed         Abstract available

  5. UEDA K, Murakami J, Tanaka T, Nakamura T, et al
    Postoperative Complications and Cancer Recurrence: Impact on Poor Prognosis of Lower Lobe Cancer.
    Ann Thorac Surg. 2020;109:1750-1756.
    PubMed         Abstract available

  6. SUN B, Kamel MK, Nasar A, Harrison S, et al
    Staple Line Thickening After Sublobar Resection: Reaction or Recurrence?
    Ann Thorac Surg. 2020;109:1670-1676.
    PubMed         Abstract available

  7. SHIMADA Y, Maehara S, Kudo Y, Masuno R, et al
    Profiles of Lung Adenocarcinoma With Multiple Ground-Glass Opacities and the Fate of Residual Lesions.
    Ann Thorac Surg. 2020;109:1722-1730.
    PubMed         Abstract available

  8. QIAN K, Krimsky WS, Sarkar SA, Deng Y, et al
    Efficiency of Electromagnetic Navigation Bronchoscopy and Virtual Bronchoscopic Navigation.
    Ann Thorac Surg. 2020;109:1731-1740.
    PubMed         Abstract available

  9. RASING MJA, Peters M, Moreno AC, Hofman EFN, et al
    Predicting incomplete resection in non-small cell lung cancer preoperatively: a validated nomogram.
    Ann Thorac Surg. 2020 Jul 30. pii: S0003-4975(20)31222.
    PubMed         Abstract available

  10. JONES GD, Caso R, Choe G, Tan KS, et al
    Intentional Segmentectomy for Clinical T1N0 Non-Small Cell Lung Cancer: Survival Differs by Segment.
    Ann Thorac Surg. 2020 Jul 30. pii: S0003-4975(20)31223.
    PubMed         Abstract available

  11. LOCOCO F, Cusumano G, Cardillo G
    It's Unnecessary to Perform N1-N2 Sampling/dissection in Predominantly-GGO cStage-I Lung Cancer?
    Ann Thorac Surg. 2020 Aug 3. pii: S0003-4975(20)31280.

    Anticancer Res

  12. CAO C, Kong MX, Kapali M, Moezardalan K, et al
    EGFR Mutated Lung Adenocarcinoma Metastasis to the Pancreas Mimicking Primary Pancreatic Ductal Carcinoma.
    Anticancer Res. 2020;40:4401-4404.
    PubMed         Abstract available

  13. CZAJKA M, Zajkowska A, Gawlak M, Bujalska-Zadrozny M, et al
    Mosaic Recombinant Adeno-associated Virus Vector rAAV/DJ/CAG for Targeted Gene Delivery to Melanoma Cells Metastasized to the Lung.
    Anticancer Res. 2020;40:4425-4444.
    PubMed         Abstract available


  14. ZHANG EW, Dagogo-Jack I, Kuo A, Rooney MM, et al
    Association between circulating tumor DNA burden and disease burden in patients with ALK-positive lung cancer.
    Cancer. 2020 Aug 5. doi: 10.1002/cncr.33118.
    PubMed         Abstract available

    Cancer Cell

  15. GOVEIA J, Rohlenova K, Taverna F, Treps L, et al
    An Integrated Gene Expression Landscape Profiling Approach to Identify Lung Tumor Endothelial Cell Heterogeneity and Angiogenic Candidates.
    Cancer Cell. 2020;37:21-36.
    PubMed         Abstract available

  16. KURPPA KJ, Liu Y, To C, Zhang T, et al
    Treatment-Induced Tumor Dormancy through YAP-Mediated Transcriptional Reprogramming of the Apoptotic Pathway.
    Cancer Cell. 2020;37:104-122.
    PubMed         Abstract available

    Cancer Lett

  17. WANG D, Cong J, Fu B, Zheng X, et al
    Immunogenic chemotherapy effectively inhibits KRAS-Driven lung cancer.
    Cancer Lett. 2020 Aug 3. pii: S0304-3835(20)30399.
    PubMed         Abstract available


  18. HOEIJMAKERS F, Heineman DJ, Daniels JM, Beck N, et al
    Variation between multidisciplinary tumor boards in clinical staging and treatment recommendations for patients with locally advanced non-small cell lung cancer.
    Chest. 2020 Jul 29. pii: S0012-3692(20)32079-1. doi: 10.1016/j.chest.2020.
    PubMed         Abstract available

    Clin Cancer Res

  19. DI FEDERICO A, Filippini DM, Dall'Olio FG, Conci N, et al
    The EGFR Exon 19 Mutant L747-A750>P Exhibits Distinct Sensitivity to Tyrosine Kinase Inhibitors in Lung Adenocarcinoma-Letter.
    Clin Cancer Res. 2020;26:518-519.

    Clin Lung Cancer

  20. CHANG Q, Xu J, Qiang H, Teng J, et al
    EGFR Tyrosine Kinase Inhibitor (TKI) Combined With Concurrent or Sequential Chemotherapy for Patients With Advanced Lung Cancer and Gradual Progression After First-Line EGFR-TKI Therapy: A Randomized Controlled Study.
    Clin Lung Cancer. 2020 Jul 6. pii: S1525-7304(20)30187.
    PubMed         Abstract available

  21. ELBANNA M, Shiue K, Edwards D, Cerra-Franco A, et al
    Impact of Lung Parenchymal-Only Failure on Overall Survival in Early-Stage Lung Cancer Patients Treated With Stereotactic Ablative Radiotherapy.
    Clin Lung Cancer. 2020 Jun 2. pii: S1525-7304(20)30164.
    PubMed         Abstract available

    Eur J Cancer

  22. SAITO S, Kadota T, Gochi M, Takagi M, et al
    Re-administration of pembrolizumab with prednisolone after pembrolizumab-induced nephrotic syndrome.
    Eur J Cancer. 2020;126:74-77.

  23. MANKOR JM, Zwierenga F, Dumoulin DW, Neefjes JJC, et al
    A brief report on combination chemotherapy and anti-programmed death (ligand) 1 treatment in small-cell lung cancer: Did we choose the optimal chemotherapy backbone?
    Eur J Cancer. 2020;137:40-44.
    PubMed         Abstract available

  24. PASSIGLIA F, Malapelle U, Del Re M, Righi L, et al
    KRAS inhibition in non-small cell lung cancer: Past failures, new findings and upcoming challenges.
    Eur J Cancer. 2020;137:57-68.
    PubMed         Abstract available

    Int J Cancer

  25. YOO JE, Han K, Shin DW, Park SH, et al
    Conditional relative survival and competing mortality in patients who underwent surgery for lung cancer: a nationwide cohort study.
    Int J Cancer. 2020 Aug 1. doi: 10.1002/ijc.33239.
    PubMed         Abstract available

    J Cancer Res Clin Oncol

  26. FRANZESE C, Bonu ML, Comito T, Clerici E, et al
    Stereotactic body radiotherapy in the management of oligometastatic and recurrent biliary tract cancer: single-institution analysis of outcome and toxicity.
    J Cancer Res Clin Oncol. 2020;146:2289-2297.
    PubMed         Abstract available

  27. KASHIWABARA K, Fujii S, Tsumura S, Sakamoto K, et al
    Overall survival of super-elderly (85 years or older) advanced non-small cell lung cancer patients with active epidermal growth factor receptor mutations receiving first-line gefitinib therapy: a single-institute retrospective study.
    J Cancer Res Clin Oncol. 2020 Aug 6. pii: 10.1007/s00432-020-03344.
    PubMed         Abstract available

  28. ZHOU X, Xu X, Tian Z, Xu WY, et al
    Mutational profiling of lung adenocarcinoma in China detected by next-generation sequencing.
    J Cancer Res Clin Oncol. 2020;146:2277-2287.
    PubMed         Abstract available

  29. LIU J, Yang X, Zhang L, Yang B, et al
    Microarray analysis of the expression profile of immune-related gene in rapid recurrence early-stage lung adenocarcinoma.
    J Cancer Res Clin Oncol. 2020;146:2299-2310.
    PubMed         Abstract available

  30. KIM SA, Kim JW, Suh KJ, Chang W, et al
    Conversion surgery after cetuximab or bevacizumab plus FOLFIRI chemotherapy in colorectal cancer patients with liver- and/or lung-limited metastases.
    J Cancer Res Clin Oncol. 2020;146:2399-2410.
    PubMed         Abstract available

  31. ZHANG Y, Deng C, Ma X, Gao Z, et al
    Ground-glass opacity-featured lung adenocarcinoma has no response to chemotherapy.
    J Cancer Res Clin Oncol. 2020;146:2411-2417.
    PubMed         Abstract available

    J Nucl Med

  32. JREIGE M, Dunet V, Letovanec I, Prior JO, et al
    Pulmonary lymphangitic carcinomatosis: diagnostic performance of HRCT and (18)F-FDG-PET/CT in correlation to clinical pathologic outcome.
    J Nucl Med. 2019 Jun 21. pii: jnumed.119.229575. doi: 10.2967/jnumed.119.229575.
    PubMed         Abstract available

    J Thorac Cardiovasc Surg

  33. FAN L, Yang H, Yu L, Wang Z, et al
    Multicenter, prospective, observational study of a novel technique for preoperative pulmonary nodule localization.
    J Thorac Cardiovasc Surg. 2020;160:532-539.
    PubMed         Abstract available

  34. NELSON DB, Antonoff MB
    Commentary: The prognostic value of Kirsten rat sarcoma viral oncogene mutation for non-small cell lung cancer: One size does not always fit all.
    J Thorac Cardiovasc Surg. 2020 Jul 5. pii: S0022-5223(20)31990.

    Lung Cancer

  35. FAN Y, Chen J, Zhou C, Wang H, et al
    Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: A phase II trial.
    Lung Cancer. 2020;147:209-213.
    PubMed         Abstract available

  36. YOUNG K, Jiang H, Marquez M, Yeung J, et al
    Retrospective study of the incidence and outcomes from lung cancer in solid organ transplant recipients.
    Lung Cancer. 2020;147:214-220.
    PubMed         Abstract available

  37. YANG G, Xu H, Yang L, Xu F, et al
    Apatinib in combination with pemetrexed-platinum chemotherapy for chemo-naive non-squamous non-small cell lung cancer: a phase II clinical study.
    Lung Cancer. 2020;147:229-236.
    PubMed         Abstract available

  38. ROJO F, Corassa M, Mavroudis D, Oz AB, et al
    International real-world study of DLL3 expression in patients with small cell lung cancer.
    Lung Cancer. 2020;147:237-243.
    PubMed         Abstract available

  39. VAD-NIELSEN J, Meldgaard P, Sorensen BS, Nielsen AL, et al
    Cell-free Chromatin Immunoprecipitation (cfChIP) from blood plasma can determine gene-expression in tumors from non-small-cell lung cancer patients.
    Lung Cancer. 2020;147:244-251.
    PubMed         Abstract available

    PLoS One

  40. KANG JK, Heo S, Kim HP, Song SH, et al
    Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    PLoS One. 2020;15:e0232754.
    PubMed         Abstract available

  41. ARIK A, Dodd E, Streftaris G
    Cancer morbidity trends and regional differences in England-A Bayesian analysis.
    PLoS One. 2020;15:e0232844.
    PubMed         Abstract available

  42. QIAN C, Liu H, Feng Y, Meng S, et al
    Clinical characteristics and risk of second primary lung cancer after cervical cancer: A population-based study.
    PLoS One. 2020;15:e0231807.
    PubMed         Abstract available

  43. FORSYTHE ML, Alwithenani A, Bethune D, Castonguay M, et al
    Molecular profiling of non-small cell lung cancer.
    PLoS One. 2020;15:e0236580.
    PubMed         Abstract available

  44. Retraction: Histone Deacetylase Inhibitors Sensitize Lung Cancer Cells to Hyperthermia: Involvement of Ku70/SirT-1 in Thermo-Protection.
    PLoS One. 2020;15:e0237589.


  45. RUPAREL M, Quaife SL, Dickson JL, Horst C, et al
    Lung Screen Uptake Trial: results from a single lung cancer screening round.
    Thorax. 2020 Aug 5. pii: thoraxjnl-2020-214703.
    PubMed         Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.